The role of triple therapy and therapy sequence in treatment of BRAF-mutant metastatic melanoma. Response to overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study

Novel therapies have achieved unprecedented benefit in survival of advanced melanoma patients. While immunotherapy (ICI) can be administered independent of mutational status, BRAF and MEK kinase inhibitors represent another effective treatment option for patients with BRAF mutant melanoma. Given the...

Descripción completa

Detalles Bibliográficos
Autores principales: Dummer, Reinhard, Welti, Michèle, Ramelyte, Egle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403899/
https://www.ncbi.nlm.nih.gov/pubmed/37543586
http://dx.doi.org/10.1186/s12967-023-04391-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403899/
https://www.ncbi.nlm.nih.gov/pubmed/37543586
http://dx.doi.org/10.1186/s12967-023-04391-1

Ejemplares similares